<?xml version="1.0" encoding="UTF-8"?><!-- generator="wordpress/2.2" -->
<rss version="2.0" 
	xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel>
	<title>Comments on: Could smaller be beautiful for restructuring pharma?</title>
	<link>http://www.reportbuyer.com/blog/could-smaller-be-beautiful-for-restructuring-pharma/</link>
	<description>Sharing intelligence</description>
	<pubDate>Wed, 07 Jan 2009 17:16:59 +0000</pubDate>
	<generator>http://wordpress.org/?v=2.2</generator>

	<item>
		<title>By: E Bailey</title>
		<link>http://www.reportbuyer.com/blog/could-smaller-be-beautiful-for-restructuring-pharma/#comment-5571</link>
		<author>E Bailey</author>
		<pubDate>Wed, 19 Sep 2007 12:30:18 +0000</pubDate>
		<guid>http://www.reportbuyer.com/blog/could-smaller-be-beautiful-for-restructuring-pharma/#comment-5571</guid>
		<description>Many of the mega-mergers in the late 1990s have probably not delivered better shareholder value than if the companies concerned had remained independent. Cynics suggest that mergers are a good way of patching up a lean R&#38;D pipeline and making some short-term savings by streamling back office functions.</description>
		<content:encoded><![CDATA[<p>Many of the mega-mergers in the late 1990s have probably not delivered better shareholder value than if the companies concerned had remained independent. Cynics suggest that mergers are a good way of patching up a lean R&amp;D pipeline and making some short-term savings by streamling back office functions.</p>
]]></content:encoded>
	</item>
</channel>
</rss>
